NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000054715

Registered date:20/06/2024

Effects of Imeglimin on Muscle Strength and Mass in Diabetic Patients

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedType 2 diabetes
Date of first enrollment2022/03/01
Target sample size60
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeThe primary endpoint was the percent change in quadriceps strength and grip strength from baseline (week 0) to week 24 in the imeglimine and control groups.
Secondary OutcomeSecondary endpoints were changes in total body muscle mass and total body fat mass from week 0 to week 24 in the imeglimine and control groups.

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteriaPatients with type 1 diabetes, patients requiring emergency response or drug adjustment (such as those with extremely poor diabetes control, repeated severe hypoglycemia, patients before and after surgery, acute infection, diabetic gangrene, and severe trauma), and patients with expected edema (including those with severe heart failure and renal failure)

Related Information

Contact

public contact
Name Takeshi Oyanagi
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, Japan Japan 216-8511
Telephone 044-977-8111
E-mail takeshi.oyanagi@marianna-u.ac.jp
Affiliation St. Marianna University School of Medicine Department of Internal Medicine, Division of Metabolism and Endocrinology
scientific contact
Name Shin Kawanabe
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, Japan Japan
Telephone 044-977-8111
E-mail s2kawanabe@marianna-u.ac.jp
Affiliation St. Marianna University School of Medicine Department of Internal Medicine, Division of Metabolism and Endocrinology